drugset / Trial / NCT02635789

Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

NCT02635789

Phase 3 Completed 62 enrolled Nobelpharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)

Timeline

Start
2015-12
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.2 % Topical